标题
Emerging classes of armed antibody therapeutics against cancer
作者
关键词
-
出版物
MedChemComm
Volume 5, Issue 4, Pages 408
出版商
Royal Society of Chemistry (RSC)
发表日期
2014-01-07
DOI
10.1039/c3md00360d
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Facile and Stabile Linkages through Tyrosine: Bioconjugation Strategies with the Tyrosine-Click Reaction
- (2013) Hitoshi Ban et al. BIOCONJUGATE CHEMISTRY
- A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology
- (2013) Scott C. Jeffrey et al. BIOCONJUGATE CHEMISTRY
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
- (2013) D. T. Teachey et al. BLOOD
- The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity
- (2013) T Hemmerle et al. BRITISH JOURNAL OF CANCER
- Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates
- (2013) Pavel Strop et al. CHEMISTRY & BIOLOGY
- Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
- (2013) S. T. Tagawa et al. CLINICAL CANCER RESEARCH
- Two-in-One antibodies with dual action Fabs
- (2013) Charles Eigenbrot et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Targeting T cells to tumor cells using bispecific antibodies
- (2013) Stanley R Frankel et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency
- (2013) Marie Vincent et al. INTERNATIONAL JOURNAL OF CANCER
- The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer
- (2013) Teresa Hemmerle et al. INTERNATIONAL JOURNAL OF CANCER
- Treatment of Triple-Negative Breast Cancer Using Anti-EGFR-Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor
- (2013) F. Al-Ejeh et al. JOURNAL OF NUCLEAR MEDICINE
- Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial
- (2013) Raymund Buhmann et al. Journal of Translational Medicine
- Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients
- (2013) Katrin S. Reiners et al. MOLECULAR THERAPY
- Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies
- (2013) Christoph Spiess et al. NATURE BIOTECHNOLOGY
- Maturing antibody–drug conjugate pipeline hits 30
- (2013) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: Radiolabeling, serum stability, and biodistribution and tumor uptake studies
- (2013) Chi Soo Kang et al. NUCLEAR MEDICINE AND BIOLOGY
- Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
- (2013) A. F. Labrijn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia
- (2013) K. L. Gutbrodt et al. Science Translational Medicine
- Antibody–cytokine fusion proteins
- (2012) Roland E. Kontermann ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Synthesis and Preclinical Evaluation of Bifunctional Ligands for Improved Chelation Chemistry of 90Y and 177Lu for Targeted Radioimmunotherapy
- (2012) Chi Soo Kang et al. BIOCONJUGATE CHEMISTRY
- Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas
- (2012) P. Gupta et al. BLOOD
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
- (2012) M. S. Topp et al. BLOOD
- Fractionated radioimmunotherapy with90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer
- (2012) Allyson J. Ocean et al. CANCER
- Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation
- (2012) S. Huang et al. CANCER RESEARCH
- Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectin-Positive Metastatic Human Melanoma Xenografts
- (2012) M. Moschetta et al. CANCER RESEARCH
- Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format
- (2012) Kathrin Zuberbühler et al. CHEMICAL COMMUNICATIONS
- Radioimmunotherapy of Fibroblast Activation Protein Positive Tumors by Rapidly Internalizing Antibodies
- (2012) E. Fischer et al. CLINICAL CANCER RESEARCH
- The Antibody-Based Delivery of Interleukin-12 to the Tumor Neovasculature Eradicates Murine Models of Cancer in Combination with Paclitaxel
- (2012) N. Pasche et al. CLINICAL CANCER RESEARCH
- Immunocytokines: a novel class of potent armed antibodies
- (2012) Nadine Pasche et al. DRUG DISCOVERY TODAY
- A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
- (2012) Silke Gillessen et al. EUROPEAN JOURNAL OF CANCER
- Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours
- (2012) G. Spitaleri et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- The Immunocytokine L19–IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF
- (2012) Kathrin Schwager et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies
- (2012) P. A. Erba et al. JOURNAL OF NUCLEAR MEDICINE
- Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma
- (2012) Francesco Papadia et al. JOURNAL OF SURGICAL ONCOLOGY
- Site-Specific Traceless Coupling of Potent Cytotoxic Drugs to Recombinant Antibodies for Pharmacodelivery
- (2012) Giulio Casi et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts
- (2012) Nasir Abbas et al. NUCLEAR MEDICINE COMMUNICATIONS
- Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
- (2012) J. Y. Axup et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature
- (2012) Martina Steiner et al. Chemical Science
- A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy
- (2011) Gonçalo J. L. Bernardes et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
- (2011) P. A. Moore et al. BLOOD
- Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey
- (2011) B. B. Aggarwal et al. BLOOD
- A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
- (2011) A Palumbo et al. BRITISH JOURNAL OF CANCER
- A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
- (2011) Gabriele Schaefer et al. CANCER CELL
- A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
- (2011) T. K. Eigentler et al. CLINICAL CANCER RESEARCH
- A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma
- (2011) S. M. Rudman et al. CLINICAL CANCER RESEARCH
- A Low-Toxicity IL-2-Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
- (2011) S. D. Gillies et al. CLINICAL CANCER RESEARCH
- Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation
- (2011) Katharina Frey et al. Integrative Biology
- Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
- (2011) Marion G. Ott et al. INTERNATIONAL JOURNAL OF CANCER
- A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth
- (2011) Rob C. Roovers et al. INTERNATIONAL JOURNAL OF CANCER
- Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7
- (2011) Nadine Pasche et al. JOURNAL OF BIOTECHNOLOGY
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Effects of a Human Dimeric Antibody Fragment 131I-AFRA-DFM5.3 in a Mouse Model for Ovarian Cancer
- (2011) A. Zacchetti et al. JOURNAL OF NUCLEAR MEDICINE
- A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma
- (2011) Anne W. Beaven et al. LEUKEMIA & LYMPHOMA
- Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
- (2011) W. Schaefer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab
- (2011) Nasir Abbas et al. EJNMMI Research
- Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase
- (2010) Simone Jeger et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma
- (2010) M Pedretti et al. BRITISH JOURNAL OF CANCER
- Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75
- (2010) M C Ryan et al. BRITISH JOURNAL OF CANCER
- Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients
- (2010) Peter Ruf et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer
- (2010) Françoise Kraeber-Bodéré et al. CANCER
- The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
- (2010) Manfred Johannsen et al. EUROPEAN JOURNAL OF CANCER
- Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial
- (2010) D. Cordier et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
- (2010) Markus M. Heiss et al. INTERNATIONAL JOURNAL OF CANCER
- Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
- (2010) Anjali Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
- (2010) Suzanne Shusterman et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
- (2010) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion
- (2010) Syd Johnson et al. JOURNAL OF MOLECULAR BIOLOGY
- The Immunocytokine F8-IL2 Improves the Therapeutic Performance of Sunitinib in a Mouse Model of Renal Cell Carcinoma
- (2010) Katharina Frey et al. JOURNAL OF UROLOGY
- Biopharmaceutical benchmarks 2010
- (2010) Gary Walsh NATURE BIOTECHNOLOGY
- Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
- (2009) Laurent Ducry et al. BIOCONJUGATE CHEMISTRY
- Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients
- (2009) S. Sauer et al. BLOOD
- A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy
- (2009) R. M. Sharkey et al. BLOOD
- Immunoglobulin G4: an odd antibody
- (2009) R. C. Aalberse et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Radiofrequency Ablation Combined with KS-IL2 Immunocytokine (EMD 273066) Results in an Enhanced Antitumor Effect against Murine Colon Adenocarcinoma
- (2009) E. E. Johnson et al. CLINICAL CANCER RESEARCH
- A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas
- (2009) T. Meyer et al. CLINICAL CANCER RESEARCH
- ErbB receptors and signaling pathways in cancer
- (2009) Nancy E Hynes et al. CURRENT OPINION IN CELL BIOLOGY
- Potent antibody drug conjugates for cancer therapy
- (2009) Peter D Senter CURRENT OPINION IN CHEMICAL BIOLOGY
- 124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy
- (2009) Bernard M. Tijink et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFα
- (2009) Enrica Balza et al. INTERNATIONAL JOURNAL OF CANCER
- Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM×Anti-CD3)
- (2009) Martin Sebastian et al. JOURNAL OF IMMUNOTHERAPY
- Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma
- (2009) R. M. Sharkey et al. JOURNAL OF NUCLEAR MEDICINE
- Intraperitoneal -Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study
- (2009) H. Andersson et al. JOURNAL OF NUCLEAR MEDICINE
- Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
- (2009) Antoni Ribas et al. Journal of Translational Medicine
- A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
- (2009) M. M. Schmidt et al. MOLECULAR CANCER THERAPEUTICS
- High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor fusion protein, in metastatic melanoma and colorectal cancer
- (2009) A. Bessard et al. MOLECULAR CANCER THERAPEUTICS
- Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
- (2009) J. Bostrom et al. SCIENCE
- Alpha-particles for targeted therapy
- (2008) George Sgouros ADVANCED DRUG DELIVERY REVIEWS
- Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab
- (2008) A. K. Gopal et al. BLOOD
- Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2
- (2008) C. Schliemann et al. BLOOD
- Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion
- (2008) R Buhmann et al. BONE MARROW TRANSPLANTATION
- Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3
- (2008) M. Amann et al. CANCER RESEARCH
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- The Targeted Immunocytokine L19-IL2 Efficiently Inhibits the Growth of Orthotopic Pancreatic Cancer
- (2008) K. Wagner et al. CLINICAL CANCER RESEARCH
- Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy
- (2008) J. Marlind et al. CLINICAL CANCER RESEARCH
- Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
- (2008) Franck Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-CD30 diabody-drug conjugates with potent antitumor activity
- (2008) K. M. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
- An engineered selenocysteine defines a unique class of antibody derivatives
- (2008) T. Hofer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
- Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase
- (2007) Angelo Fontana et al. ADVANCED DRUG DELIVERY REVIEWS
- The Biology of Interleukin-2
- (2007) Thomas R. Malek Annual Review of Immunology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now